INDV-1000
Pharmaceutical compound
From Wikipedia, the free encyclopedia
INDV-1000 is a GABAB receptor positive allosteric modulator (PAM) which is under development for the treatment of substance-related disorders.[1][2][3] Its route of administration is unspecified.[1] The drug is under development by Indivior in partnership with Addex Therapeutics.[1][2][3] As of April 2024, it is in the preclinical research stage of development.[1][2][3] The chemical structure of INDV-1000 does not yet appear to have been disclosed.[1] It is one of a limited number of known GABAB receptor PAMs as of 2024.[4][5]
Other namesINDV1000
Routes of
administrationUnspecified[1]
administrationUnspecified[1]
| Clinical data | |
|---|---|
| Other names | INDV1000 |
| Routes of administration | Unspecified[1] |
| Drug class | GABAB receptor positive allosteric modulator |
